Neuronetics Announces 510(k) Clearance of MT Cap Technology for NeuroStar® Advanced Therapy for Mental Health

Monday, December 20, 2021

Neuronetics, Inc., a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced today that they have received 510(k) clearance on their MT Cap technology for NeuroStar® Advanced Therapy for Mental Health. A limited launch of the technology will begin in the coming weeks, with a national rollout in Q1 2022.

“We’re delighted to bring to market this latest in a series of technologies designed to make the motor threshold determination process simpler and more efficient for clinicians,” stated Cory Anderson, VP of Clinical Affairs and Medical Operations. “We appreciate the ongoing collaboration with FDA that enabled a quick and efficient review process.”

The MT Cap provides a target starting location and step-by-step map to guide the process of identifying a patient’s motor threshold (MT) and reduce multiple steps during the initial assessment for NeuroStar. The MT Cap leverages NeuroStar’s unique floating coil locking system, making mapping and determining motor thresholds seamless. Determining and locating a patient’s motor threshold is a critical component of the treatment process and can take up to 30 minutes for each patient. Now, when the MT Cap is combined with the recently launched Fast MT, these technology innovations provide an average 40% time savings during the MT activity.

NeuroStar is the leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder, with over 4 million treatments delivered and thousands of lives transformed.

Latest Issue
Get instant
access to our latest e-book
Sanofi UpperEdge - Healthcare ERP Transformation Medical Manufacturing Asia 2022 Medical Fair Asia 2022